Concepedia

Zainab Jagani

ZJ

Statistics

Publications

15

Citations

3.3K

H-Index

15

Active since

2003

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

Novartis Institutes for BioMedical Research

Dana-Farber Cancer Institute

Harvard University

Zainab Jagani is an author at Novartis (Switzerland) specializing in medicine, cell biology, and tumor biology.

Top concepts

Publications per year

2003–2021

15

Publications

15

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening

E. Robert McDonald, Antoine de Weck, Michael R. Schlabach et al. · Cell · 2017 · 687 citations · Full text

, , +13

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

Susan Wee, Zainab Jagani, Kay X. Xiang et al. · Cancer Research · 2009 · 451 citations

ARID1B is a specific vulnerability in ARID1A-mutant cancers

Katherine Helming, Xiaofeng Wang, Boris G. Wilson et al. · Nature Medicine · 2014 · 418 citations · Full text

Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers

Gregory R. Hoffman, Rami Rahal, Frank P. Buxton et al. · Proceedings of the National Academy of Sciences · 2014 · 405 citations · Full text

Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway

Zainab Jagani, E. Lorena Mora‐Blanco, Courtney G. Sansam et al. · Nature Medicine · 2010 · 252 citations · Full text

, , +8

1–5 of 15